Chronic myeloid leukemia-transplantation in the tyrosine kinase era

Hematol Oncol Clin North Am. 2014 Dec;28(6):1037-53. doi: 10.1016/j.hoc.2014.08.002. Epub 2014 Oct 5.

Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) revolutionized the outlook for many patients with chronic myeloid leukemia (CML) in the 1980s. The introduction of the tyrosine kinase inhibitors (TKIs) nearly 15 years ago displaced HSCT as the first-line treatment for most CML patients. However, in the twenty-first century HSCT remains a viable treatment option for many patients with CML. This review focuses on the role of HSCT for CML in the TKI era, paying particular attention to patient selection and transplant outcome.

Keywords: Allogeneic stem cell transplant; Chronic myeloid leukemia; Tyrosine kinase inhibitors.

Publication types

  • Review

MeSH terms

  • Benzamides / therapeutic use
  • Hematopoietic Stem Cell Transplantation / methods*
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
  • Piperazines / therapeutic use
  • Protein Kinase Inhibitors / therapeutic use*
  • Pyrimidines / therapeutic use
  • Remission Induction
  • Transplantation, Homologous
  • Treatment Outcome

Substances

  • Benzamides
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Imatinib Mesylate